Provided by Tiger Fintech (Singapore) Pte. Ltd.

AzurRx Biopharma Inc.

3.45
+0.0000
Volume:- -
Turnover:2.20M
Market Cap:34.33M
PE:-0.22
High:3.45
Open:3.45
Low:3.45
Close:3.45
Loading ...

BioMedNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Aims to Identify Best Delivery Method for Lead Drug Candidate

StreetInsider
·
23 Dec 2020

BioMedNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Advancing MS1819 in Fight to Improve Treatment of EPI in CF, CP Patients

StreetInsider
·
12 Dec 2020

BRIEF-AzurRx Bio Says Co Granted 180-Day Extension To June 1 To Regain Compliance With Listing Requirement

Reuters
·
07 Dec 2020

AzurRx BioPharma Announces First Patients Dosed in Turkey for Phase 2 Combination Therapy Trial of MS1819 in Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency

GlobeNewswire
·
30 Nov 2020

InvestorBrandNetwork (IBN) Announces Latest Episode of Stock2Me Podcast Featuring AzurRx Biopharma Inc. President & CEO James Sapirstein

StreetInsider
·
24 Nov 2020

BioMedNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Featured in Simply Wall St Article

StreetInsider
·
21 Nov 2020

AzurRx BioPharma Inc. (NASDAQ: AZRX) Making Strides with MS1819 Clinical Trials for Cystic Fibrosis-Associated Pancreatic Insufficiency

StreetInsider
·
18 Nov 2020

BRIEF-Azurrx Biopharma Says Co Has Regained Compliance With Nasdaq Listing Rule

Reuters
·
18 Nov 2020

BRIEF-AzurRx Biopharma Requests Protocol Amendment To Phase 2b OPTION 2 Study Of MS1819 In Cystic Fibrosis Patients

Reuters
·
17 Nov 2020

AzurRx BioPharma Requests Protocol Amendment to Phase 2b OPTION 2 Study of MS1819 in Cystic Fibrosis Patients

GlobeNewswire
·
17 Nov 2020

BRIEF-Azurrx Biopharma Identifies Asymchem As Potential Partner Of Choice For MS1819 Phase 3 Clinical Trial Drug Production

Reuters
·
10 Nov 2020

AzurRx BioPharma Identifies Asymchem as Potential Partner of Choice for MS1819 Phase 3 Clinical Trial Drug Production

GlobeNewswire
·
10 Nov 2020

AzurRx BioPharma Provides Insight into Drawbacks of Using Porcine Products in Production of Pharmaceuticals and Medicinals, Offers Update on Efforts to Produce Synthetic Alternatives

GlobeNewswire
·
30 Oct 2020

Azurrx Biopharma CEO Issues Letter To Shareholders

T-Reuters
·
07 Oct 2020

AzurRx BioPharma to Present at the 2020 H.C. Wainwright 22nd Annual Global Investment Conference (September 14) and the LD 500 Virtual Conference (September 4)

GlobeNewswire
·
31 Aug 2020

AZRX: 1H:21 Readout for OPTION 2 and Combo Trials

Zacks Small Cap Research
·
26 Aug 2020

AzurRx BioPharma Announces First Patients Dosed in Phase 2b OPTION 2 Clinical Trial of MS1819 in Cystic Fibrosis

GlobeNewswire
·
13 Aug 2020

AzurRx BioPharma CEO Issues Clarifying Statement to Shareholders

GlobeNewswire
·
13 Aug 2020

AZRX: MS1819 Update: Interim Data

Zacks Small Cap Research
·
13 Aug 2020